默沙东正与中国制药企业走向深度合作。 2025年3月25日，默沙东与恒瑞医药达成一项潜在交易规模近20亿美元的交易。默沙东获得恒瑞医药一 款在研药物中国之外的权益。这是默沙东与中国本土企业达成的一系列深入合作的最新案例之一。 默沙东凭借其多元治疗领域的创新产品发展，全球收入规模超过640亿美元。默沙东深耕中国三十余 年，而近十年来中国本土制药产业生态迅速成长。中国制药产业发展，默沙东不断扩大的市场影响力， 共同塑造了中国与默沙东之间的研发和知识产权新型纽带。 新伙伴 3月25日，默沙东从恒瑞医药取得HRS-5346独家许可权。 默沙东是一家历史超过130年的制药企业，在全球140多个国家/地区开展业务。恒瑞医药是一家专注科 技创新的国际化制药企业，HRS-5346 是其开发的一种在研口服小分子脂蛋白(a)抑制剂，目前在中国进 行 II 期临床试验评估。 Lp(a)血清浓度升高是动脉粥样硬化性心血管疾病有据可查的风险因素，全球每五个成年人中就可能有 一人受此影响[1]。HRS-5346 是一种在研的口服小分子Lp(a)抑制剂，这将有力拓展并补充默沙东在心血 管代谢疾病领域的研发管线。根据协议，恒瑞医药授予默沙东 ...

Core Viewpoint - The company, Heptagon Pharmaceuticals (和铂医药-B), experienced a significant stock price increase following the announcement of its interim financial results, reflecting strong revenue growth and strategic partnerships [1] Financial Performance - The company reported revenue of approximately $101 million, representing a year-on-year increase of about 327% [1] - Net profit for the period was $72.99 million, showing a remarkable year-on-year growth of 5,125% [1] - Revenue from licensing fees increased from $20.8 million to $93.7 million, primarily due to strategic collaborations with global pharmaceutical companies and new product licenses [1] - Research services and technology licensing revenue rose by 164.9%, from $2.9 million to $7.6 million [1] Strategic Partnerships - In March 2025, the company entered into a global strategic collaboration with AstraZeneca to co-develop next-generation bispecific antibodies targeting immune diseases, tumors, and other conditions [1] - The collaboration includes the use of Heptagon's proprietary fully human antibody technology platform, Harbour Mice, for multiple projects across various therapeutic areas [1] - As part of this agreement, the company is set to receive up to approximately $4.6 billion in upfront and milestone payments, along with tiered royalties based on net sales [1]

Core Viewpoint - The company has signed a technical development cooperation contract with Shanghai Lekuang Huilin Pharmaceutical Technology Co., Ltd. for the joint development of the STC007 injection project, with a total milestone payment of 200 million yuan (including tax) [1] Group 1 - The collaboration aims to accelerate the commercialization process of the STC007 injection, providing more treatment options for clinical needs [1] - STC007 injection is primarily used for the treatment of moderate to severe pain following abdominal surgery and is currently in the Phase III clinical trial stage [1] - The execution of the contract is expected to have a positive impact on the company's current and future operating performance [1]